You can buy or sell ESPR and other stocks, options, ETFs, and crypto commission-free!
Esperion Therapeutics, Inc. operates as a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). It offers Bempedoic acid and Ezetime combination pill as therapies that have been shown to lower elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. Read More The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
Ann Arbor, Michigan
52 Week High
52 Week Low
Research And Development
Guru FocusMar 14
Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $243,650 of Shares
President & CEO of Esperion Therapeutics Inc (NASDAQ:ESPR) Timothy M Mayleben bought 5,000 shares of ESPR on 03/14/2019 at an average price of $48.73 a share.
Markets InsiderMar 14
Bempedoic Acid Study 1 Results Published in The New England Journal of Medicine Demonstrates Significant LDL-Cholesterol Lowering and Reduced Marker of Underlying Cardiovascular Inflammation, with...
Bempedoic acid is an oral, once-daily ATP Citrate Lyase (ACL) Inhibitor that reduces cholesterol and fatty acid synthesis in the liver Study 1 is the largest of a comprehensive five Phase 3 study programme investigating the benefits of bempedoic acid in patients requiring additional low-density lipoprotein cholesterol (LDL-C) lowering Over 52-weeks, bempedoic acid was observed to be well-tolerated, and did not lead to higher overall adverse events compared with placebo Treated patients showed lower rates...
Markets InsiderMar 13
Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine
– Study 1 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP – – Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated, and Did Not Lead to Higher Overall Adverse Events Compared With Placebo – – Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor that Reduces Cholesterol and Fatty Acid Synthesis in the Liver – – Research by Professor Kausik Ray, published in the March 14th, 2019 New England Journal of Medicine – ANN ARBOR, Mich., Marc...
Expected May 1, After Hours